Senate committee's abortion drug probe reveals oversight concerns

A thirteen-year-old with a phone and a credit card can now order abortion pills online with no doctor ever laying eyes on her. That's not a hypothetical from some Senate hearing room. That's what an undercover purchase actually turned up. Sit with that for a second before you decide this is just another partisan skirmish over reproductive policy.

This isn't really about the abortion debate at all, or shouldn't be. It's about what happens when telehealth and mail-order pharma outrun the systems meant to check them. We've spent years hearing that expanded access to abortion pills was about convenience and privacy for adult women making adult decisions. Nobody sold the public on a system so porous that a middle schooler can slip through it. If a company selling any other prescription drug had this kind of gap, verifying age, verifying medical necessity, verifying anything, there would be a recall and a congressional hearing inside a week.

The people who built this system don't want to talk about the thirteen-year-old. They want to talk about "access" and "barriers to care," as if asking a website to confirm a buyer isn't a child is some kind of oppressive hurdle. It isn't. It's the same basic safeguard we expect from a liquor store or a gun dealer, applied to a drug that carries real physical risk and is now apparently a few clicks away for a kid.

Congress ought to treat this the way it would treat any other product safety failure, because that's what it is. Regulators approved a loosened distribution model, telehealth companies ran with it, and nobody built in the guardrails that basic common sense would demand. Fix that, and you're not relitigating Roe. You're just doing the job oversight exists to do.